Pipeline
Pipeline Overview
BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory illnesses
Candidate
Preclinical
Phase 1
Phase 2
Oncology
Targeted Indication1L STK11m NSCLC
1L STK11m NSCLC
Phase 1b/2a
Targeted Indication2L NSCLC
2L NSCLC
Phase 2
Mipasetamab
uzoptirine
uzoptirine
Targeted IndicationSolid Tumors
Solid Tumors
Phase 1
Severe
respiratory
infections
Targeted IndicationARDS
ARDS
Preclinical
Fibrosis
Targeted IndicationFibrotic Diseases
Fibrotic Diseases
Phase 1
Note : Bemcentinib is also being studied in Investigator Led Trials in glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.